Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
124 hedge funds and large institutions have $2.08B invested in Verve Therapeutics in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 55 increasing their positions, 16 reducing their positions, and 21 closing their positions.
275% more call options, than puts
Call options by funds: $16M | Put options by funds: $4.26M
244% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 16
199% more capital invested
Capital invested by funds: $696M → $2.08B (+$1.39B)
110% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 21
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
23% more funds holding
Funds holding: 101 → 124 (+23)
7.63% more ownership
Funds ownership: 93.65% → 101.28% (+7.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$70M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$69.1M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$43.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$33.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$32.3M |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$16M |
| 3 |
Millennium Management
New York
|
-$11.9M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$10.5M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.06M |
VERV Hedge Fund Activity: Q3 2022 in Review
124 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2022, worth a combined $2.08B — up 199% from $696M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new VERV positions and 21 closed out — a net gain of 23 holders — while 55 added to existing stakes and 16 trimmed.
The largest buyer was State Street, adding an estimated $70M. The largest seller was Citadel Advisors, cutting an estimated $32.3M.
- 124 institutional investors held Verve Therapeutics (VERV) as of Q3 2022, up from 101 in Q2 2022.
- Funds reported $2.08B of Verve Therapeutics stock for Q3 2022, up 199% quarter-over-quarter.
- 44 funds opened new Verve Therapeutics positions in Q3 2022 and 21 closed out, a net change of +23 holders.
- The largest Verve Therapeutics buyer in Q3 2022 was State Street, an estimated $70M added.
- The largest Verve Therapeutics seller in Q3 2022 was Citadel Advisors, an estimated $32.3M sold.
Based on aggregated 13F filings for Q3 2022.